Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.

Marina Chiara Garassino,Shirish M. Gadgeel,Delvys Rodriguez Abreu,Enriqueta Felip,Emilio Esteban,G. Speranza,Maximilian Hochmair,Steven Francis Powell,Edward B. Garon,Rina Hui,Naoyuki Nogami,Razvan Cristescu,Michael Morrissey,Andrey Loboda,J Kobie,Mark Ayers,Bilal Piperdi,M.C. Pietanza,Alexandra Snyder,Martin Reck

Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.

2020

9521Background: In a previous analysis of KEYNOTE-189 (NCT02578680), we showed that tissue TMB (tTMB) assessed by whole-exome sequencing was not significantly associated with efficacy in either arm...

Keywords:

Oncology
Pemetrexed
Chemotherapy
first line therapy
Pathology
Internal medicine
Pembrolizumab
Medicine
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations